Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Capecitabine in Metastatic Colorectal Cancer
NCT00506168Phase 2Terminated
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2001
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan and capecitabine in metastatic colorectal cancer (mCRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Maximal response rate and Toxicities. Started Nov 2001; status: terminated.
02
Drugs
irinotecancapecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00506168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506168.